Skip to main content

Table 4 Recurrence predictors of site-specific recurrence by Cox regression analysis

From: Risk stratification for predicting postoperative recurrence of gastric cancer by grade of venous invasion

Parameters

Hematogenous recurrence (n = 17)

Nodal recurrence (n = 11)

Peritoneal recurrence (n = 14)

 

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

Univariate analysis

 Age

1.044 (0.994–1.096)

0.008

1.116 (1.034–1.203)

0.005

1.071 (1.009–1.136)

0.024

 Sex (Male)

1.510 (0.492–4.633)

0.472

0.591 (0.180–1.938)

0.385

1.221 (0.383–3.897)

0.736

 Location (Lower)

3.210 (0.922–11.173)

0.067

1.830 (0.485–6.901)

0.372

0.942 (0.327–2.715)

0.911

 Surgery (TG)

0.310 (0.071–1.356)

0.120

0.890 (0.236–3.355)

0.863

1.276 (0.427–3.810)

0.663

 Lymph node dissection (D2)

1.463 (0.557–3.845)

0.440

1.265 (0.386–4.146)

0.698

1.075 (0.376–3.070)

0.893

 Synchronous multiple GCs (Yes)

1.188 (0.271–5.195)

0.819

0.841 (0.107–6.578)

0.869

0.646 (0.084–4.945)

0.674

 Macroscopic type (3 + 4)

2.343 (0.865–6.347)

0.094

2.707 (0.790–9.277)

0.113

6.333 (2.184–18.363)

0.001

 Depth of tumor invasion

2.232 (1.436–3.470)

< 0.001

6.074 (2.348–15.711)

< 0.001

3.985 (2.071–7.668)

< 0.001

 Histology (por sig nec)

1.126 (0.778–1.628)

0.529

1.418 (0.851–2.364)

0.180

1.608 (0.981–2.636)

0.060

 Cancer stromal volume (sci)

0.978 (0.340–2.817)

0.968

2.714 (0.827–8.903)

0.100

8.086 (2.254–29.011)

0.001

 Tumor infiltration pattern (INFc)

0.753 (0.278–2.035)

0.575

3.838 (1.017–14.479)

0.047

8.689 (1.942–38.882)

0.005

 VI grade

3.845 (2.331–6.343)

< 0.001

2.513 (1.402–4.505)

0.002

3.157 (1.846–5.397)

< 0.001

 Lymphatic invasion (Yes)

18.491 (2.448–139.653)

0.005

88.559 (0.639–12265.7)

0.075

7.574 (1.691–33.931)

0.008

 Nodal metastasis

2.407 (1.608–3.602)

< 0.001

4.057 (2.062–7.983)

< 0.001

2.444 (1.585–3.771)

< 0.001

 Resection margin status (R1 + R2)

6.932 (2.252–21.332)

0.001

11.132 (2.899–42.745)

< 0.001

4.899 (1.072–22.396)

0.040

 pTNM stage

3.638 (1.898–6.974)

< 0.001

16.017 (2.661–96.403)

0.002

7.631 (2.759–21.107)

< 0.001

 Neoadjuvant chemotherapy (Yes)

4.697 (0.621–35.531)

0.134

0.049 (0.000- 3.3E + 09)

0.812

0.049 (0.000–2.474E + 8)

0.791

 Adjuvant chemotherapy (Yes)

5.844 (1.880–18.165)

0.002

7.492 (1.551–36.194)

0.012

3.926 (1.310–11.765)

0.015

Multivariate analysis

 VI grade

3.145 (1.809–5.470)

< 0.001

1.495 (0.681–3.280)

0.316

2.090 (1.092–3.999)

0.026

 pTNM stage

2.099 (1.023–4.309)

0.043

14.189 (2.275–88.511)

0.005

5.759 (1.978–16.769)

0.001

  1. HR hazard ratio, CI confidence interval, TG total gastrectomy, GC gastric cancer, por poorly differentiated adenocarcinoma, either solid or poorly cohesive type, sig signet-ring cell carcinoma, nec neuroendocrine carcinoma, VI venous invasion, pTNM pathological tumor node metastasis